Noesis Capital Mangement Corp Has $15.95 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Noesis Capital Mangement Corp raised its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 2.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 118,689 shares of the medical research company's stock after acquiring an additional 3,382 shares during the quarter. Agilent Technologies comprises approximately 3.0% of Noesis Capital Mangement Corp's investment portfolio, making the stock its 11th biggest holding. Noesis Capital Mangement Corp's holdings in Agilent Technologies were worth $15,945,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. CKW Financial Group boosted its holdings in Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company's stock valued at $25,000 after acquiring an additional 100 shares during the last quarter. Global X Japan Co. Ltd. lifted its position in Agilent Technologies by 161.1% during the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after purchasing an additional 116 shares during the period. Ashton Thomas Securities LLC bought a new position in shares of Agilent Technologies in the 3rd quarter valued at about $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Agilent Technologies during the 3rd quarter worth approximately $38,000. Finally, Hanson & Doremus Investment Management raised its stake in shares of Agilent Technologies by 66.5% during the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock worth $35,000 after buying an additional 105 shares during the last quarter.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the transaction, the chief executive officer now owns 39,652 shares of the company's stock, valued at $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Agilent Technologies Stock Down 0.6 %

Shares of NYSE A traded down $0.71 during midday trading on Monday, reaching $127.21. The company's stock had a trading volume of 1,092,566 shares, compared to its average volume of 1,734,113. Agilent Technologies, Inc. has a fifty-two week low of $124.16 and a fifty-two week high of $155.35. The stock has a 50 day simple moving average of $140.64 and a 200-day simple moving average of $139.18. The stock has a market capitalization of $36.29 billion, a price-to-earnings ratio of 29.21, a PEG ratio of 3.59 and a beta of 1.11. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The firm had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Equities research analysts predict that Agilent Technologies, Inc. will post 5.57 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.78%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies's dividend payout ratio (DPR) is 22.76%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Bank of America reduced their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. StockNews.com upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Tuesday, December 24th. Robert W. Baird dropped their price objective on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a research note on Thursday. JPMorgan Chase & Co. decreased their target price on Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating for the company in a research note on Tuesday, November 26th. Finally, Wells Fargo & Company lowered their price target on Agilent Technologies from $157.00 to $155.00 and set an "overweight" rating for the company in a report on Monday, December 9th. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $146.15.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.